Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ECOZA vs EXSEL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.
Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.
Topical treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis
Treatment of tinea versicolor (pityriasis versicolor),Management of dandruff and seborrheic dermatitis of the scalp
For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.
1-2 mg orally once daily; maximum dose 2 mg/day.
Terminal elimination half-life is approximately 24–30 hours, allowing for once-daily dosing.
Terminal half-life: 12-18 hours (mean 15 h); requires dose adjustment in renal impairment (Cr Cl <30 m L/min).
Not extensively metabolized; minimal systemic absorption after topical application.
Minimal systemic absorption after topical application; any absorbed selenium is primarily excreted in urine, with minor metabolism via reduction to selenides and methylation to dimethylselenide.
Primarily hepatic metabolism; <1% excreted renally as unchanged drug. Fecal excretion accounts for ~57% of metabolites.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Approximately 89–93% bound to plasma proteins, primarily albumin.
95% bound to albumin and alpha-1-acid glycoprotein.
Apparent volume of distribution is approximately 2–3 L/kg, indicating extensive tissue penetration.
0.8-1.2 L/kg; indicates extensive extravascular distribution.
Oral bioavailability is approximately 37% (range 20–70%) due to first-pass metabolism; topical bioavailability is negligible systemically.
Oral: 60-80%; first-pass metabolism reduces bioavailability by 20-40%.
No dosage adjustment required for renal impairment. Systemic absorption is minimal after topical or intravaginal use.
No adjustment required for mild to moderate impairment. Severe impairment (GFR <30 m L/min): contraindicated.
No dosage adjustment required for hepatic impairment due to minimal systemic absorption.
Child-Pugh A: no adjustment. Child-Pugh B or C: contraindicated.
Safety and efficacy in pediatric patients have not been established for vaginal use. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily; duration based on clinical response. Weight-based dosing not applicable.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
No specific dose adjustment required; use same dosing as for younger adults. Monitor for local irritation or adverse effects.
Start at 1 mg orally once daily; titrate cautiously due to increased risk of falls and hypotension.
None
None.
For external use only; avoid contact with eyes; discontinue if hypersensitivity occurs.
Avoid contact with eyes, eyelids, and mucous membranes. If contact occurs, rinse thoroughly with water. Discontinue if local irritation or sensitization develops. Use with caution in patients with inflamed or broken skin due to increased absorption risk. Not for use on large areas of the body for prolonged periods.
Known hypersensitivity to imidazole antifungals or any component of the formulation
Hypersensitivity to selenium sulfide or any component of the formulation. Do not use on broken or inflamed skin.
No clinically significant food interactions for topical econazole nitrate. Avoid alcohol if using oral antifungal concurrently (not applicable here).
No known food interactions.
ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topical application, unlikely to cause fetal harm; however, prolonged use near term is not recommended due to theoretical risk of premature ductus arteriosus closure if systemic absorption occurs.
Pregnancy Category D. First trimester: Associated with Ebstein's anomaly and other congenital heart defects; avoid if possible. Second and third trimesters: Risk of fetal hyperthyroidism or hypothyroidism, cranial synostosis, intellectual disability, and neonatal goiter if maternal hyperthyroidism is treated with this drug. Use only if clearly needed and maternal benefit outweighs fetal risk.
Not known if econazole is excreted in human milk. M/P ratio not available. Due to low systemic absorption after topical use, risk to nursing infant is considered low. Caution if applied to breast area; avoid infant ingestion.
Excreted in human milk. M/P ratio not available. Potential for serious adverse reactions in nursing infants, including thyroid dysfunction and arrhythmias. Decision to discontinue nursing or drug based on importance of drug to mother.
No dose adjustment needed. Pharmacokinetic changes in pregnancy (e.g., increased skin blood flow, hydration) may slightly alter absorption but clinical significance is minimal. Use standard topical dosing as prescribed.
Pregnancy may increase clearance of this drug; dose adjustments often not required, but individualize based on maternal thyroid function and clinical response. Lower doses may be needed to avoid fetal hypothyroidism.
Ecoza (econazole nitrate) is a topical azole antifungal. Avoid use on open wounds or broken skin. Apply once daily for 4 weeks for tinea pedis; 2 weeks for tinea cruris/corporis. Do not use occlusive dressings. Monitor for local irritation, burning, or allergic contact dermatitis.
EXSEL (selenium disulfide) 2.5% shampoo: Use twice weekly for 2 weeks, then once weekly for maintenance. Limit application to 5-10 minutes before rinsing. Avoid contact with eyes or broken skin. Can cause temporary hair discoloration (especially on bleached or permed hair). May stain jewelry and clothing. For dandruff and seborrheic dermatitis of the scalp.
Apply a thin layer to cleaned, dry affected area and surrounding skin once daily or as directed.,Wash hands before and after application unless treating hands.,Use for the full prescribed duration even if symptoms improve to prevent recurrence.,Avoid contact with eyes, mouth, or mucous membranes. If contact occurs, rinse with water.,Do not cover the treated area with bandages or wrappings unless instructed by your doctor.,Inform your doctor if symptoms persist after 2 weeks or worsen, or if severe irritation occurs.,Store at room temperature away from moisture and heat.
Shake bottle well before use.,Wet hair thoroughly before applying shampoo.,Apply enough shampoo to lather and massage into scalp for 2-3 minutes.,Leave on scalp for 5 minutes (up to 10 minutes) before rinsing thoroughly.,Rinse hair and scalp completely to avoid residue.,Use twice weekly for first 2 weeks, then once weekly as directed.,Avoid contact with eyes; if contact occurs, rinse thoroughly with water.,Do not use on broken or irritated skin.,Discontinue use and consult doctor if rash or irritation develops.,May stain clothing and jewelry; rinse thoroughly after use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ECOZA vs EXSEL, answered by our medical review team.
ECOZA is a Topical Antifungal that works by Imidazole antifungal inhibiting ergosterol synthesis via CYP51, disrupting fungal cell membrane permeability.. EXSEL is a Topical Antifungal that works by Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ECOZA and EXSEL depend on the specific clinical indication. These are both Topical Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ECOZA is: For vulvovaginal candidiasis: One vaginal suppository (150 mg) inserted intravaginally at bedtime for 3 consecutive days. For cutaneous candidiasis: Apply cream (1%) to affected area twice daily for 2-4 weeks.. The standard adult dose of EXSEL is: 1-2 mg orally once daily; maximum dose 2 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ECOZA and EXSEL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ECOZA is classified as Category C. ECOZA (econazole nitrate) is pregnancy category C. First trimester: no adequate studies; avoid unless benefit outweighs risk. Second/third trimester: minimal absorption after topic. EXSEL is classified as Category C. Pregnancy Category D. First trimester: Associated with Ebstein's anomaly and other congenital heart defects; avoid if possible. Second and third trimesters: Risk of fetal hyperthyr. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.